ArticleJournal of clinical medicine2020
Clarithromycin Versus Metronidazole in First-Line
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Evidence-based clinical practice guidelines for peptic ulcer disease 2026.Journal of gastroenterology · 2026Guideline
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Evidence-based clinical practice guidelines for peptic ulcer disease 2020.Journal of gastroenterology · 2021Guideline
- Vonoprazan-Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.Cureus · 2024Article
- Salivary glands - a new site of Helicobacter pylori occurrence.Journal of applied biomedicine · 2024Article
- Bismuth-Based Quadruple Therapy for Clarithromycin-ResistantGut and liver · 2022Article
- Current guidelines forWorld journal of clinical cases · 2022Review
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- The status and progress of first-line treatment againstTherapeutic advances in gastroenterology · 2021Review
- Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis.Journal of clinical medicine · 2020Article
- High Antibiotic Resistance ofMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInternational treatment guidelines for
methodsRandomized control trials (RCTs) comparing eradication rates between PAC and PAM first-line treatment up to December 2018 were included. We divided RCTs into four groups based on resistance to CAM (< 15% or ≥ 15%) and MNZ (< 15% or ≥ 15%).
resultsA total of 27 studies (4825 patients) were included. Overall eradication rates between PAC and PAM were similar (74.8% and 72.5%, relative risk (RR): 1.13, 95% confidence interval (CI): 0.91-1.39,
conclusionsOverall eradication rates with PAC and PAM were equivalent worldwide. In low MNZ-resistance areas, PAM may be recommended as first-line therapy. However, the efficacy of PAC may be insufficient, irrespective of susceptibility to CAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.